Evaluating tumor necrosis factor-alpha and interleukin 17 as plasma biomarkers for rheumatoid arthritis diagnosis
DOI:
https://doi.org/10.15584/ejcem.2025.4.17Keywords:
anti-cyclic citrullinated peptide, biomarkers, rheumatoid arthritisAbstract
Introduction and aim. Rheumatoid arthritis (RA) is a complex chronic inflammatory autoimmune disease with significant global health implications. In this study, our aim was to evaluate the clinical utility of plasma tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) along with immunological parameters as diagnostic biomarkers for patients with RA.
Material and methods. A case-control study was conducted involving 75 RA cases and 75 age- and sex-matched controls. Plasma levels of TNF-α and IL-17 were measured using ELISA kits. Statistical analyses included receiver operating characteristic (ROC) curve analysis and correlation tests to evaluate the diagnostic accuracy, predictive value, and associations with disease activity parameters.
Results. RA patients exhibited significantly elevated TNF-α (275.5±99.9 vs. 46.2±8.4 pg/mL, p<0.001) and IL-17 (313.8±95.4 vs. 42.2±10.96 pg/mL, p<0.001) compared to controls. Patients with a family history of RA had higher TNF-α (p=0.019) and IL-17 (p=0.03) levels. ROC analysis revealed perfect diagnostic accuracy for both biomarkers (100% sensitivity and specificity) at cut-offs >65.2 pg/mL (TNF-α) and >83 pg/mL (IL-17).
Conclusion. There was a positive correlation between serum levels of IL-17 and TNF-α. Therefore, these biomarkers distinguish rheumatoid arthritis patients from healthy controls.
Downloads
References
O'Neil LJ, Alpízar-Rodríguez D, Deane KD. Rheumatoid Arthritis: The Continuum of Disease and Strategies for Prediction, Early Intervention, and Prevention. J Rheumatol. 2024;51(4):337-349. doi: 10.3899/jrheum.2023-0334
Smith MH, Berman JR. What Is Rheumatoid Arthritis? JAMA. 2022;327(12):1194. doi: 10.1001/jama.2022.0786
Shi W, Liang X, Zhang H, et al. Burden of rheumatoid arthritis in India from 1990 to 2021: insights from the Global Burden of Disease Database. Front Med. 2025;12:1526218. doi: 10.3389/fmed.2025.1526218
Gabal MMA, Eldin AB, Elserwy MA, Mohammed MA. Simplified vs modified (reduced) ultrasound 6 joint score in assessing disease activity in rheumatoid arthritis patients. Eur J Clin Exp Med. 2024;22(1):36-44. doi: 10.15584/ejcem.2024.1.4
Uke P, Maharaj A, Adebajo A. A review on the epidemiology of rheumatoid arthritis: An update and trends from current literature. Best Pract Res Clin Rheumatol. 2025;39(1):102036. doi: 10.1016/j.berh.2025.102036
Finckh A, Gilbert B, Hodkinson B, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591-602. doi: 10.1038/s41584-022-00827-y
Almutairi KB, Nossent JC, Preen DB, Keen HI, Inderjeeth CA. The prevalence of rheumatoid arthritis: a systematic review of population-based studies. J Rheumatol. 2021;48(5):669-676. doi: 10.3899/jrheum.200367
Black RJ, Cross M, Haile LM, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(10):e594-610. doi: 10.1016/S2665-9913(23)00211-4
Hussein OA, El-Toukhy MA, El-Rahman HS. Neutrophil CD64 expression in inflammatory autoimmune diseases: its value in distinguishing infection from disease flare. Immunol Invest. 2010;39(7):699-712. doi: 10.3109/08820139.2010.491520
Togashi T, Ishihara R, Watanabe R, et al. Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis. J Clin Med. 2025;14(5):1529. doi: 10.3390/jcm14051529
Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci. 2019;20(23):6008. doi: 10.3390/ijms20236008
Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021;22(20):10922. doi: 10.3390/ijms222010922
Jang DI, Lee AH, Shin HY, et al. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int J Mol Sci. 2021;22(5):2719. doi: 10.3390/ijms22052719
Orsini F, Crotti C, Cincinelli G, et al. Bone involvement in rheumatoid arthritis and spondyloartritis: an updated review. Biology. 2023;12(10):1320. doi: 10.3390/biology12101320
Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023;23(1):38-54. doi: 10.1038/s41577-022-00746-9
Sun L, Wang L, Moore BB, et al. IL-17: Balancing Protective Immunity and Pathogenesis. J Immunol Res. 2023;2023:3360310. doi: 10.1155/2023/3360310
Taams LS. Interleukin-17 in rheumatoid arthritis: Trials and tribulations. J Exp Med. 2020;217(3):e20192048. doi: 10.1084/jem.20192048
Gremese E, Tolusso B, Bruno D, Perniola S, Ferraccioli G, Alivernini S. The forgotten key players in rheumatoid arthritis: IL-8 and IL-17 – Unmet needs and therapeutic perspectives. Front Med. 2023;10:956127. doi: 10.3389/fmed.2023.956127
Gail MH, Haneuse S. Power and sample size for case-control studies. In: Handbook of statistical methods for case-control studies. New York: Chapman and Hall/CRC; 2018: 163–188. doi: 10.1201/9781315154084
Venetsanopoulou AI, Alamanos Y, Voulgari P V, Drosos AA. Epidemiology and Risk Factors for Rheumatoid Arthritis Development. Mediterr J Rheumatol. 2023;34(4):404-413. doi: 10.31138/mjr.301223.eaf
Zhang Z, Gao X, Liu S, et al. Global, regional, and national epidemiology of rheumatoid arthritis among people aged 20–54 years from 1990 to 2021. Sci Rep. 2025;15(1):10736. doi: 10.1038/s41598-025-92150-1
Zen M, Salmaso L, Amidei CB, et al. AB1628 the incidence and prevalence of rheumatoid arthritis in Italy in the last decade. Ann Rheum Dis. 2023;82(1):2048. doi: 10.1136/annrheumdis-2023-eular.1432
Hashim ZM, Abdulameer KA. The Effects of -806 T/C and -857 T/C Single Nucleotide Polymorphisms in the TNF-α Gene on Rheumatoid Arthritis Severity and Inflammatory Markers. Al-Rafidain J Med Sci. 2024;6:188–194. doi: 10.54133/ajms.v6i1.517
Mosavi E, Bandehpour M, Mostafazadeh A, et al. Plasma TNF-α Elevation in Biologic Naive Rheumatoid Arthritis Patients Belonging to a Population with New Mutations in TLR4 and CYP51A1 genes without Association with Disease-Related Antibodies Levels. Int J Mol Cell Med. 2024;13(2): 171-185. doi: 10.22088/IJMCM.BUMS.13.2.171
Farrugia M, Baron B. The role of TNF-α in rheumatoid arthritis: a focus on regulatory T cells. J Clin Transl Res. 2016;2(3):84-90. doi: 10.18053/jctres.02.201603.005
Forsey RJ, Thompson JM, Ernerudh J, et al. Plasma cytokine profiles in elderly humans. Mech Ageing Dev. 2003;124(4):487-493. doi: 10.1016/S0047-6374(03)00025-3
Gerli R, Monti D, Bistoni O, et al. Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians. Mech Ageing Dev. 2001;121(1–3):37-46. doi: 10.1016/S0047-6374(00)00195-0
Anaya JM, Lozada-Martinez ID, Torres I, Shoenfeld Y. Autoimmunity in centenarians. A paradox. J Transl Autoimmun. 2024;8:100237. doi: 10.1016/j.jtauto.2024.100237
Pinti M, Gibellini L, Lo Tartaro D, et al. A comprehensive analysis of cytokine network in centenarians. Int J Mol Sci. 2023;24(3):2719. doi: 10.3390/ijms24032719
Samimi Z, Kardideh B, Chalabi M, Zafari P, Taghadosi M. The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs). Braz J Pharm Sci. 2020;56:e18551. doi: 10.1590/s2175-97902019000418551
Julià A, López-Lasanta M, Blanco F, et al. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy. BMC Musculoskelet Disord. 2021;22(1):372. doi: 10.1186/s12891-021-04248-y
Samaan SF, Taha SI, Mahmoud FA, Elsaadawy Y, Khalil SA, Gamal DM. Role of Interleukin-17 in Predicting Activity of Rheumatoid Arthritis and Systemic Lupus Erythematosus. Clin Med Insights Arthritis Musculoskelet Disord. 2024;17. doi: 10.1177/11795441241276880
Selimov P, Karalilova R, Damjanovska L, et al. Rheumatoid arthritis and the proinflammatory cytokine IL-17. Folia Med (Plovdiv). 2023;65(1):53-59. doi: 10.3897/folmed.65.e72448
Wang J, He L, Li W, Lv S. A Role of IL-17 in Rheumatoid Arthritis Patients Complicated With Atherosclerosis. Front Pharmacol. 2022;13:828933. doi: 10.3389/fphar.2022.828933
Robert M, Miossec P. IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels. Front Med. 2018;5:364. doi: 10.3389/fmed.2018.00364
Hwang SY, Kim JY, Kim KW, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther. 2004;6(2):R120-R128. doi: 10.1186/ar1038
Farag MA, El Debaky FE, Abd El-Rahman SM, Abd el-khalek SM, Fawzy RM. Serum and synovial fluid interleukin-17 concentrations in rheumatoid arthritis patients: Relation to disease activity, radiographic severity and power Doppler ultrasound. Egypt Rheumatol. 2020;42(3):171-175. doi: 10.1016/j.ejr.2020.02.009
Nasef N, Elnagdy M, Younis W, et al. Helper 17 cells and interleukin-17 in patients with rheumatoid arthritis. Int J Clin Rheumatol. 2019;14(3):113-119.
Atwa SE, Azab MM, Mohamed MS. Serum Interleukin-17 level in patients with rheumatoid arthritis and its relation to disease activity. Zagazig Univ Med J. 2020;26(1):87-93.
Okutan İ, Aci R, Keskin Â, Bilgin M, Kızılet H. New inflammatory markers associated with disease activity in rheumatoid arthritis: pan-immune-inflammation value, systemic immune-inflammation index, and systemic inflammation response index. Reumatologia. 2024;62(6):439-446. doi: 10.5114/reum/196066
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
